Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| SMG-SNU Boramae Medical Center | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study was to compare the effects of limaprost(Opalmon® ) on walking ability, low back pain and leg pain after transforaminal epidural steroid injection (TFESI) was administered compared to the placebo group.
This study is a prospective, randomized, comparative clinical study that is assigned to a placebo group or a trial group before transforaminal epidural steroid injection (TFESI) is performed.
The subjects of the study will receive an explanation of the study and decide to participate voluntarily in patients who have decided to undergo TFESI for neurogenic claudication and low back pain or leg pain due to lumbar spinal canal stenosis (LSS).
All study subjects are presented with TFESI at the level appropriate for their symptoms in the operating room and then returned to the recovery room. All participants will be monitored for non-invasive blood pressure, electrocardiography, heart rate, and peripheral oxyven saturation during and after the procedure.
Patients assigned to the placebo group will take placebo three times a day and one tablet once from the first day after receiving TFESI. Patients assigned to the trial group will take limaprost (Opalmon®) three times a day, one tablet once from the first day after receiving TFESI. In both groups, the drug was administered for 12 weeks.
In both groups, during the first 4 weeks, no drug changes or additional procedures were observed, and only Acetaminophen was allowed as a rescue drug.
After TFESI, visits at 4 weeks, 8 weeks and 12 weeks to collect each measurement variable.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients who received placebo after transforminal epidural steroid injection | Placebo Comparator | Patients who took placebo for 12 weeks after TFESI |
|
| Patients who received limaprost (Opalmon®) after transforaminal epidural steroid injection | Experimental | Patients who took limaprost (Opalmon®) for 12 weeks after TFESI |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transforaminal epidural steroid injection (TFESI) | Procedure | Well trained pain physician performs all the fluoroscopy-guided transforaminal epidural steroid injection (TFESI), who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For TFESI, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under fluoroscopy guidance at the patient's symptom complaining level. After confirming with a contrast medium, 3 ml of 0.1875% ropivacaine and 5 mg of dexamethasone are administered. |
| Measure | Description | Time Frame |
|---|---|---|
| ODI (Oswestry Disability Index) change | The change in ODI compared to the baseline was measured at the outpatient visit. | 4 weeks after placebo or limaprost (Opalmon®) |
| Measure | Description | Time Frame |
|---|---|---|
| ODI (Oswestry Disability Index) change | The change in ODI compared to the baseline was measured at the outpatient visit. | 8 weeks after placebo or limaprost (Opalmon®) |
| ODI (Oswestry Disability Index) change |
Not provided
Inclusion Criteria:
Patients aged 18 to 85 years
Patients with a new or known diagnosis of lumbar spinal stenosis on Magnetic Resonance Imaging (MRI)
Patients scheduled to undergo TFESI due to low back pain or leg pain
Exclusion Criteria:
Refusal of a patient
Coagulopathy
Systemic infection or local infection at the needle injection site
Patients with lumbar instability
Neoplasms in the needle path
Allergy to amide-type local anesthetics
Decreased cognition to the extent that NRS is incomprehensible
Patients with peripheral vascular disease (including peripheral arterial disease)
Patients taking anticoagulant or antiplatelet drugs
Patients with severe cardiovascular disease or liver or kidney disease
Patinets with cerebral infarction
Patinets with a history of gastrointestinal bleeding
Patinets who have had lumbar spine surgery or are expected to receive it within 12 months
Patients who show positive in the straight leg elevation test
Patients who are allergic or sensitive to limaprost (Opalmon®) and placebo or their ingredients
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Youn Moon Jee, MD, PhD | Contact | 821052992036 | jymoon0901@gmail.com | |
| Jeongsoo Kim, MD | Contact | 821047346422 | dreamsu457@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Youn Moon Jee, MD, PhD | Seoul National University Hospital | Study Director |
| Jeongsoo Kim, MD | SMG-SNU Boramae Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Hospital | Recruiting | Seoul | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013130 | Spinal Stenosis |
| ID | Term |
|---|---|
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
The change in ODI compared to the baseline was measured at the outpatient visit.
| 12 weeks after placebo or limaprost (Opalmon®) |
| Treadmill test change | The change in treadmill test compared to the baseline was measured at the outpatient visit. | 4 weeks after placebo or limaprost (Opalmon®) |
| Treadmill test change | The change in treadmill test compared to the baseline was measured at the outpatient visit. | 8 weeks after placebo or limaprost (Opalmon®) |
| Treadmill test change | The change in treadmill test compared to the baseline was measured at the outpatient visit. | 12 weeks after placebo or limaprost (Opalmon®) |
| Numeric Rating Scale (NRS) change | The change in NRS compared to the baseline was measured at the outpatient visit. | 4 weeks after placebo or limaprost (Opalmon®) |
| Numeric Rating Scale (NRS) change | The change in NRS compared to the baseline was measured at the outpatient visit. | 8 weeks after placebo or limaprost (Opalmon®) |
| Numeric Rating Scale (NRS) change | The change in NRS compared to the baseline was measured at the outpatient visit. | 12 weeks after placebo or limaprost (Opalmon®) |
| Euroqol-5 Dimensions Questionnaire (EQ-5D) change | The change in EQ-5D compared to the baseline was measured at the outpatient visit. | 4 weeks after placebo or limaprost (Opalmon®) |
| Euroqol-5 Dimensions Questionnaire (EQ-5D) change | The change in EQ-5D compared to the baseline was measured at the outpatient visit. | 8 weeks after placebo or limaprost (Opalmon®) |
| Euroqol-5 Dimensions Questionnaire (EQ-5D) change | The change in EQ-5D compared to the baseline was measured at the outpatient visit. | 12 weeks after placebo or limaprost (Opalmon®) |
| Beck Depression Inventory (BPI) change | The change in BPI compared to the baseline was measured at the outpatient visit. | 4 weeks after placebo or limaprost (Opalmon®) |
| Beck Depression Inventory (BPI) change | The change in BPI compared to the baseline was measured at the outpatient visit. | 8 weeks after placebo or limaprost (Opalmon®) |
| Beck Depression Inventory (BPI) change | The change in BPI compared to the baseline was measured at the outpatient visit. | 12 weeks after placebo or limaprost (Opalmon®) |
| Changes in analgesic drugs | The change in analgesic drugs compared to the baseline was measured at the outpatient visit. | 12 weeks after placebo or limaprost (Opalmon®) |